Public health and clinical advisory · Version 1.3

7-OH is not just kratom, and the transition may be abrupt.

Concentrated 7-hydroxymitragynine products can create opioid-like dependence and withdrawal. DEA's pending temporary scheduling action may reduce future harm, but dependent patients need a treatment bridge before retail access changes.

Check current legal status before counseling patients. DEA's July 6, 2026 Federal Register notice states that a temporary scheduling order may be published on or after August 5, 2026 and will take effect on publication. This page is written for clinical preparation, not legal advice.

What is happening?

The Drug Enforcement Administration issued a notice of intent to temporarily place 7-hydroxymitragynine above a specified threshold into Schedule I of the Controlled Substances Act. The notice covers 7-OH, including possible isomers, esters, ethers, salts, and related forms, when above the stated threshold. The proposed threshold includes botanical material containing more than 0.050% 7-OH by dry weight, and alternative articles or processed dosage forms containing more than 0.050% 7-OH by weight/weight, weight/volume, volume/volume, or more than 1.00 mg per article.

Once the temporary order is published, qualifying products become subject to Schedule I regulatory controls and civil and criminal sanctions. That means products patients may have bought openly at smoke shops, gas stations, and online can become legally risky very quickly.

Start here

Choose the resource you need

Patients and families Recognize withdrawal, identify urgent warning signs, and find a route to care. Clinicians Screen exposure, triage risk, and use a structured opioid-withdrawal treatment frame. Clinical assessment appendix Printable exposure, disposition, and treatment-planning template. Chemistry and testing Understand what a drug test can—and cannot—establish.

Why schedule these products at all?

Concentrated 7-OH is not ordinary kratom leaf. FDA describes 7-OH products as novel potent opioid products that have not been proven safe or effective for any use and should be avoided. DEA describes a market of tablets, gummies, shots, powders, sublingual films, and related products with variable dose, uncertain purity, inconsistent composition, and high abuse potential.

From a public health perspective, removing high-potency, poorly labeled opioid-active products from ordinary retail shelves is reasonable. The problem is not the recognition of risk. The problem is the transition for already-dependent patients.

Why this is not garden-variety opioid withdrawal

7-OH has important mu-opioid receptor activity. The mu-opioid receptor is the receptor most associated with opioid analgesia, euphoria, respiratory depression, tolerance, dependence, and withdrawal. Preclinical and clinical sources describe 7-OH as substantially more opioid-like than mitragynine, and concentrated products may deliver a stronger exposure than natural kratom preparations.

But this is not simply heroin withdrawal with different packaging. Kratom alkaloid products can involve mixed pharmacology, including stimulant-like effects at lower kratom exposures, opioid effects at higher exposures, and possible adrenergic, serotonergic, and mood-related effects from the broader alkaloid context. There is no standard clinical category called a gamma-opioid receptor in routine receptor nomenclature; the relevant clinical issue is the atypical mu, delta, kappa, biased-signaling, and non-opioid context.

Clinically, some patients have rapid interdose withdrawal, severe insomnia, dysphoria, GI distress, autonomic symptoms, anxiety, agitation, and intense craving. COWS can be useful, but it may undercapture the syndrome. In one published high-dose withdrawal case, a patient taking 360 mg/day presented about 48 hours after the last dose with prominent nausea, diarrhea, cramping, restlessness, chills, clamminess, and anxiety, while the recorded COWS was only 5.

What withdrawal may look like

Early/interdoseHeavy users may feel withdrawal within hours: anxiety, sweating, restlessness, dysphoria, chills, or GI activation.
12 to 48 hoursSymptoms often become obvious: insomnia, nausea, diarrhea, abdominal cramping, myalgias, autonomic arousal, and craving.
Days 2 to 4This may be the acute peak. Hydration, agitation, polysubstance withdrawal, impulsive fentanyl substitution, and unsafe self-treatment become major concerns.
After acute withdrawalSleep disruption, fatigue, anxiety, dysphoria, and craving may persist after the GI and autonomic symptoms begin to improve.

Who needs earlier triage?

High daily dose or hourly redosingSuggests severe dependence and rapid interdose withdrawal.
Seizure disorder or severe insomniaWithdrawal, sleep deprivation, and polysubstance use may lower the safety margin.
Cardiac disease, frailty, pregnancy, very young or older ageAutonomic stress, dehydration, and poor oral intake matter more.
Polysubstance useAlcohol, benzodiazepines, fentanyl, stimulants, gabapentinoids, and nicotine can change the risk profile.
Complex medication metabolismCYP interactions, sedatives, serotonergic medications, adrenergic agents, and hepatic impairment can complicate treatment.
Psychiatric instability or unstable housingProlonged withdrawal and supply loss can trigger panic, relapse, or unsafe substitution.

A practical clinical approach

There is no universally accepted 7-OH detoxification guideline. Published reports and early case series support pragmatic use of standard opioid use disorder tools, including buprenorphine, adjunctive medications, harm reduction, careful follow-up, and individualized induction strategy.

A reasonable first-pass algorithm is to define the exposure, determine dependence severity, risk stratify the patient, match the treatment setting, and actively prevent fentanyl substitution. Ask about product name, labeled milligrams, actual frequency, redosing interval, route, duration, cost per day, withdrawal timing, failed quit attempts, polysubstance use, and whether the patient would consider fentanyl or pills if 7-OH disappeared tomorrow.

For buprenorphine, do not dose by the clock alone. Anchor standard induction to convincing objective withdrawal, or consider a low-dose initiation when timing is unclear, the patient is medically fragile, or the risk of precipitated withdrawal or destabilization is high. Adjuncts may include clonidine or lofexidine when appropriate, antiemetics, antidiarrheals, NSAIDs/acetaminophen, muscle relaxants when safe, hydration support, sleep planning, and close monitoring.

Human metabolism · analytical toxicology · evidence limits

Chemistry and testing: what the result means

Botanical kratom, mitragynine-rich extracts, concentrated 7-OH, mitragynine pseudoindoxyl, and newer semisynthetic analogues are not interchangeable exposures. Product labels may not reliably identify their alkaloid content.

A positive 7-OH test is not source proof Humans can form 7-OH from mitragynine. A positive 7-OH result alone does not establish direct use of a concentrated 7-OH product.
Routine opioid screens can miss it Routine opiate immunoassays should not be used to rule kratom-family exposure in or out. When compound-level identification matters, request targeted LC-MS/MS or high-resolution mass spectrometry.
Do not use a fixed detection window Detection depends on dose, repeated use, specimen matrix, assay sensitivity, health status, and the compounds measured. Published botanical studies do not establish a universal window for high-dose purified 7-OH.
Preserve the product when it matters If management, reporting, or legal interpretation depends on source, retain the tablet, film, gummy, powder, or packaging for product analysis when feasible.

Technical references: chemistry, metabolism, and detection · pharmacology and testing

Why the transition matters

Scheduling can reduce initiation while increasing near-term danger among already-dependent users. These patients may not identify as having opioid use disorder. Many believe they are using a supplement, a kratom derivative, a pain reliever, a mood aid, or a legal smoke-shop product. When supply changes abruptly, some will seek treatment. Some will stockpile. Some will abruptly stop. Some will search for stronger opioids, including fentanyl.

The public health task is not simply to remove 7-OH from shelves. It is to make sure dependent patients are seen before they reach the cliff edge.

Care, consultation, and education

Consultation, referrals, and talks

Brian Harris, MD is board-certified in Addiction Medicine, Anesthesiology, and Sleep Medicine. EusomniaMD Recovery provides evaluation, treatment planning, and care coordination for substance-use disorders, including alcohol, opioids, benzodiazepines, stimulants, nicotine, kratom, and concentrated 7-OH.

Patient referrals and appointments: (650) 308-4845 · office@eusomniamd.com

Clinician, institutional, and press inquiries: bharris@eusomniamd.com

Fax: (925) 204-6417. This resource is educational and does not replace individualized medical care, emergency care, or legal advice.

Selected references

  1. DEA. Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I. Federal Register, 91 FR 40917. July 6, 2026.
  2. FDA. Products Containing 7-OH Can Cause Serious Harm. Consumer Update.
  3. FDA. FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers. July 29, 2025.
  4. Lybik N, Cone B, Skelton S, Elfessi Z. Management of acute withdrawal from 7-hydroxymitragynine after high-dose chronic use: A case report. J Am Pharm Assoc. 2026. doi:10.1016/j.japh.2026.103047.
  5. Fenske E, Williams B, Hallock-Koppelman L, Buchheit BM. Buprenorphine for the Management of 7-Hydroxymitragynine Use: A Retrospective Case Series. J Addict Med. 2026. doi:10.1097/ADM.0000000000001723.
  6. Sharma A, Nair BS, Pemminati S. 7-Hydroxymitragynine and Nicotine Pouch Withdrawal Syndrome: A Case Report. Cureus. 2025. doi:10.7759/cureus.98386.

This page is educational and does not replace individualized medical care, emergency care, or legal advice. If someone is unresponsive or having difficulty breathing, call 911. Poison Help: 1-800-222-1222.